BRD7的亚细胞定位及其假定核输出信号序列的分离与鉴

BRD7被鉴定为一个鼻咽癌密切相关新基因和潜在的核转录调节因子．通过绿色荧光蛋白(GFP)介导的亚细胞定位方法,系统研究BRD7在非洲绿猴肾COS7细胞、人宫颈癌HeLa细胞以及人鼻咽癌HNE1细胞中的亚细胞定位,发现BRD7主要定位在细胞核,呈细点状或条梭状分布,3株细胞中没有明显的细胞类型差异．通过对BRD7编码蛋白氨基酸序列进行比对分析,发现了1个具有亮氨酸富集特征的假定核输出信号序列pNES,该区域具有类似核输出信号特征序列“ L-x(2,3)-［LIVFM］-x(2,3)-L-x-［LI］ "（X代表任意氨基酸）的结构;通过功能分析,发现它不具有介导异源蛋白GFP胞浆定位的功能,且其亚细胞定位或胞浆/胞核分布比例不受细霉素B(leptomycin B)干预的影响,说明这个pNES不具核输出信号结构域的功能,不是BRD7的核输出信号．     

BRD7核定位信号的结构分析和功能鉴定

目的:对BRD7的核定位信号进行预测、结构分析和功能鉴定,并考察其对BRD7亚细胞定位的影响。方法:通过生物信息学对BRD7的核定位信号进行预测和结构分析,然后利用绿色荧光蛋白(GFP)介导的直接荧光和间接免疫荧光定位方法分别对核定位信号的功能进行鉴定,并考察其对BRD7亚细胞定位的影响。结果:BRD7的65～96位氨基酸残基具有潜在核定位信号(NLS)的结构特征,该核定位信号包含3簇碱性氨基酸残基,可视为由2个紧密相邻、部分重叠的双向核靶序列NLS1和NLS2组成;并发现NLS及其构成上的NLS1和NLS2均具有介导异源蛋白GFP胞核定位的功能,从而证实BRD7的65～96位残基为BRD7功能性核定位信号所在区域,且单簇碱性氨基酸残基的缺失不足以破坏其核定位信号的功能;同时发现野生型BRD7呈胞核分布,而核定位信号缺失型BRD7主要呈胞浆分布。结论:BRD7的65～96位氨基酸残基为BRD7功能性核定位信号所在区域,在BRD7胞核分布模式中发挥了十分重要的作用。     

BRD7 mediates hyperglycaemia‐induced myocardial apoptosis via endoplasmic reticulum stress signalling pathway

Bromodomain‐containing protein 7 (BRD7) is a tumour suppressor that is known to regulate many pathological processes including cell growth, apoptosis and cell cycle. Endoplasmic reticulum (ER) stress‐induced apoptosis plays a key role in diabetic cardiomyopathy (DCM). However, the molecular mechanism of hyperglycaemia‐induced myocardial apoptosis is still unclear. We intended to determine the role of BRD7 in high glucose (HG)‐induced apoptosis of cardiomyocytes. In vivo, we established a type 1 diabetic rat model by injecting a high‐dose streptozotocin (STZ), and lentivirus‐mediated short hairpin RNA (shRNA) was used to inhibit BRD7 expression. Rats with DCM exhibited severe myocardial remodelling, fibrosis, left ventricular dysfunction and myocardial apoptosis. The expression of BRD7 was up‐regulated in the heart of diabetic rats, and inhibition of BRD7 had beneficial effects against diabetes‐induced heart damage. In vitro, H9c2 cardiomyoblasts was used to investigate the mechanism of BRD7 in HG‐induced apoptosis. Treating H9c2 cardiomyoblasts with HG elevated the level of BRD7 via activation of extracellular signal‐regulated kinase 1/2 (ERK1/2) and increased ER stress‐induced apoptosis by detecting spliced/active X‐box binding protein 1 (XBP‐1s) and C/EBP homologous protein (CHOP). Furthermore, down‐regulation of BRD7 attenuated HG‐induced expression of CHOP via inhibiting nuclear translocation of XBP‐1s without affecting the total expression of XBP‐1s. In conclusion, inhibition of BRD7 appeared to protect against hyperglycaemia‐induced cardiomyocyte apoptosis by inhibiting ER stress signalling pathway.     

染色质乙酰化相关BRD蛋白家族

Bromodomain结构域首先在果蝇蛋白质Brahma中发现,折叠模式独特且高度保守,是最早也是截至目前公认唯一可与乙酰化赖氨酸结合的结构域。BRD蛋白通过结合不同的蛋白质或者定位蛋白质到细胞核发挥精细调节作用。BRD蛋白复合物常特异性识别并结合到染色质组蛋白H3/H4特定的乙酰化赖氨酸残基,从而影响靶基因的转录翻译;该蛋白复合物功能异常通常与多种疾病的发生相关联,表明对转录翻译调节有重要意义。但迄今为止,BRD蛋白复合物修饰染色质机理不明,现有研究提示BRD蛋白复合物维持染色质乙酰化状态,也可以与染色质组蛋白其它位点结合,从整体水平增强组蛋白乙酰化精度和效率。     

候选抑瘤基因 BRD7 及家族蛋白的功能研究进展

溴区结构（bromodomain）是近年来发现的广泛分布于多种生物中的一种高度保守的结构域,溴区结构蛋白通过参与信号依赖性的基因转录调控而广泛参与细胞内重要的生命活动．BRD7基因是1999年克隆的一个新的bromodomain基因,GenBank登录号为AF152604或AF152605．eMotif分析表明,BRD7蛋白包含多个磷酸化位点和一个保守bromodomain功能域,Blast显示BRD7蛋白与人的Celtix-1及鼠的bromodomain蛋白BP75具有高度的同源性．利用转基因技术已证实,在鼻咽癌细胞系HNEl中过表达BRD7基因可以抑制其细胞生长和细胞周期G1-S的进程,并部分逆转鼻咽痛细胞HNE1的恶性表型．为了全面地揭示BRD7基因的细胞内生物学功能,深入了解BRD7基因的细胞内整体信息流向,中南大学肿瘤研究所细胞遗传室已从上、中、下游三个不同层面对BRD7基因的功能研究展开了初步的探索．     

候选抑瘤基因 BRD7 及家族蛋白的功能研究进展

溴区结构(bromodomain)是近年来发现的广泛分布于多种生物中的一种高度保守的结构域,溴区结构蛋白通过参与信号依赖性的基因转录调控而广泛参与细胞内重要的生命活动.BRD7基因是1999年克隆的一个新的bromodomain基因,GenBank登录号为AF152604或AF152605.eMotif分析表明,BRD7蛋白包含多个磷酸化位点和一个保守bromodomain功能域,Blast显示BRD7蛋白与人的Celtix-1及鼠的bromodomain蛋白BP75具有高度的同源性.利用转基因技术已证实,在鼻咽癌细胞系HNE1中过表达BRD7基因可以抑制其细胞生长和细胞周期G1-S的进程,并部分逆转鼻咽癌细胞HNE1的恶性表型.为了全面地揭示BRD7基因的细胞内生物学功能,深入了解BRD7基因的细胞内整体信息流向,中南大学肿瘤研究所细胞遗传室已从上、中、下游三个不同层面对BRD7基因的功能研究展开了初步的探索.     

BRD7基因调控区的克隆与功能研究

BRD7基因是采用cDNA代表性差异分析法克隆得到的一个新的Bromodomain基因(GenBank登录号AF152604).它在鼻咽癌细胞和组织中表达明显下调,过表达BRD7基因能部分逆转鼻咽癌细胞的恶性表型.为了揭示BRD7基因在鼻咽癌细胞和组织中表达下调的分子机制,利用生物信息学技术已预测出其启动子区.荧光素酶活性检测结果表明该区域具有强启动子活性;转录因子Sp1特异性地结合于BRD7该启动子区;Sp1特异性阻断剂mithramycinA能明显地抑制BRD7启动子的活性和BRD7基因的表达.     

Preparation of polyclonal antibody specific for BRD7 and detection of its expression pattern in the human fetus.

BRD7 is a novel bromodomain gene. It plays critical role in cell growth, cell cycle progression, and signal-dependent gene expression. Overexpression of the BRD7 gene in nasopharyngeal carcinoma cells is effective to inhibit cell growth and cell cycle progression from G1 to S phase. However, little is known about its bio-functions because of the unavailability of a specific BRD7 antibody. In this study, for the first time, we generated a highly specific BRD7 antibody. It is able to specifically recognize recombinant GST-BRD7N protein with a molecular mass of 65 kDa and recognize BRD7-Myc and endogenously expressed BRD7 protein with an approximate molecular mass of 75 kDa, which corresponds well with the calculated molecular mass of the BRD7 protein. More importantly, with these antisera, we analyzed BRD7 distribution in the human fetus by Western blot and immunohistochemistry assays. Obvious nuclear expression of BRD7 protein presents in human cerebellum, pancreas, intestines, liver, and kidney. Cardiomyocyte shows high cytoplasm expression of the BRD7 protein. Weak nuclear expression of the BRD7 protein is found in human cerebrum, lung, and stomach. These data may help to further study the cellular role of the BRD7 gene. In particular, the prepared BRD7 antibody will be helpful for studying the bio-functions of endogenously expressed BRD7 protein.     

Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells

Oesophageal cancer is one of the most frequent solid malignancies and the leading cause of cancer‐related death around the world. It is urgent to develop novel therapy strategies to improve patient outcomes. Acetylation modification of histones has been extensively studied in epigenetics. BRD4, a reader of acetylated histone and non‐histone proteins, has involved in tumorigenesis. It has emerged as a promising target for cancer therapy. BRD4 inhibitors, such as JQ1, have exerted efficacious anti‐proliferation activities in diverse cancers. However, the effects of JQ1 on oesophageal cancer are still not fully described. Here, we demonstrate that JQ1 suppresses cell growth and triggers cellular senescence in KYSE450 cells. Mechanistically, JQ1 up‐regulates p21 level and decreases cyclin D1 resulting in G1 cycle arrest. The inhibitory effects of JQ1 on KYSE450 cells are independent on apoptosis. It activates cellular senescence by increasing SA‐β‐gal activity. BRD4 knockdown by shRNA recapitulates cellular senescence. We also display that administration of JQ1 decreases recruitment of BRD4 on the promoter of aurora kinases A and B. Inhibitors targeting at AURKA/B phenocopy JQ1 treatment in KYSE450 cells. These results identify a novel action manner of BRD4 in oesophageal cancer, which strengthens JQ1 as a candidate drug in oesophageal cancer chemotherapy.     

Binding pocket-based design,synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors

Bromodomain-containing protein 4 (BRD4), consisting of two tandem bromodomains (BD1 and BD2), is key epigenetic regulator in fibrosis and cancer, which has been reported that BD1 and BD2 have distinct roles in post-translational modification. But there are few selective inhibitors toward those two domains. Herein, this study designed and synthesized a series of novel selective BRD4-BD1 inhibitors, using computer-aided drug design (CADD) approach focused on exploring the difference of the binding pockets of BD1 and BD2, and finding the His437 a crucial way to achieve BRD4-BD1 selectivity. Our results revealed that the compound 3u is a potent selective BRD4-BD1 inhibitor with IC₅₀ values of 0.56?μM for BD1 but >100?μM for BD2. The compound exhibited a broad spectrum of anti-proliferative activity against several human cancer and fibroblastic cell lines, which might be related to its capability of reducing the expression of c-Myc and collagen I. Furthermore, it could induce apoptosis in A375 cells. To the contrary, the selective BD2 inhibitor, RVX-208, did not indicate any of these activities. Our findings highlight that the function of BRD4-BD1 might be predominant in fibrosis and cancer. And it is rational to further develop novel selective BRD4-BD1 inhibitors.     

鼻咽癌侯选抑瘤基因BRD7原核表达载体的构建及其表达

BRD7基因是一个鼻咽癌侯选抑瘤基因,为了构建BRD7基因的原核表达载体并使其在大肠杆菌得到表达,设计了带有SalⅠ,NotⅠ酶切位点的引物,以已构建好的质粒pGEM-T Easy/BRD7为模板,用PCR扩增出BRD7基因的完整阅读框架,并用SalⅠ,NotⅠ酶切PCR产物和原核表达载体PGEX-4T-2,然后用T4 DNA连接酶将其连接,得到重组表达质粒PGEX-4T-2/BRD7,经双酶切鉴定和测序验证,表达载体构建正确.重组表达质粒转化感受态大肠杆菌Jm105后用IPTG诱导,成功表达了一分子质量约为90 ku的融合蛋白;37℃诱导4 h后,SDS-聚丙烯酰胺凝胶(PAGE)电泳后,经扫描分析该融合蛋白产量占菌体蛋白总量28.48%, 蛋白质印迹(Western-blot)证实了该融合蛋白的表达获得成功.这为BRD7基因的蛋白纯化及抗体制备,进一步开展其功能研究奠定了基础.